References

  1. The Miracle Enzyme is Serrapeptase.’ Quality Enzymes. n.p. n.d. Web. 30 April, 2011.
  2. Al-Khateeb TH, Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. Int J Oral Maxillofac Surg. 2008;37(3): 264-268
  3. What is Serrapeptase?’ Live Strong. n.p. 06th July, 2010. Web. 30 April, 2011.
  4. Silk Worm Enzymes for Carotid Artery Blockage. Naturally Healthy Publications. n.d. Web. 2 March, 2013.
  5. Mico´-Llorens JM, Satorres-Nieto M, Gargallo-Albiol J, Arnabat- Domı´nguez J, Berini-Ayte´s L, Gay- Escoda C. Efficacy of methylprednisolone in controlling complications after impacted lower third molar surgical extraction. Eur J Clin Pharmacol. 2006;62(9):693-698.
  6. Ustun Y, Erdogan O, Esen E, Karsli ED. Comparison of the effects of 2 doses of methylprednisolone on pain, swelling, and trismus after third molar surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003: 96: 535-539.
  7. Graziani F, D’Aiuto F, Arduino PG, Tonelli M, Gabriele M. Perioperative dexamethasone reduces post-surgical sequelae of wisdom tooth removal. A split mouth randomized double-masked clinical trial. Int J Oral Maxillofac Surg. 2006: 35: 241-246.
  8. Al-Khateeb TH, Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. Int J Oral Maxillofac Surg. 2008;37(3):264-268.
  9. Esch PM, Gerngross H, Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase- a prospective study. Fortschr Med. 1989;107:67-68.
  10. Kee WH, Tan SL, Lee V, Salmon YM. The treatment of breast engorgement with Serrapeptase (Danzen): a randomized double-blind controlled trial. Singapore Med J 1989: 30: 48-54.
  11. Klein G, Kullich W. Short-term treatment of painful osteoarthritis of the knee with oral enzymes: randomised, doubleblind study versus Diclofenac. Clin Drug Invest 2000;19:15-23.
  12. Lee HS, Majima Y, Sakakura Y, Kim BW. A technique for quantitative cytology of nasal secretions. Eur Arch Otorhinolaryngol. 1991;248:406-408.
  13. Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A, Russo S, Guarini E, Vesperini G. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind randomized trial versus placebo. J Int Med Res. 1990;18:379-388.
  14. Mecikoglu M, Saygi B, Yildirim Y, Karadag-Saygi E, Ramadan SS, Esemenli T. The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infection. J Bone Joint Surg Am. 2006;88:1208-1214.
  15. Nakamura S, Hashimoto Y, Mikami M, Yamanaka E, Soma T, Hino M, Azuma A, Kudoh S. Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Respirology. 2003;8:316-320.
  16. Panagariya A, Sharma AK. A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome. J Assoc Physicians India 1999;47:1170-1172.
  17. Selan L, Berlutti F, Passariello C, Comodi-Ballanti MR, Thaller MC. Proteolytic enzymes: a new treatment strategy for prosthetic infections. Antimicrob Agents Chemother. 1993;37:2618-2621.
  18. Tachibana M, Mizukoshi O, Harada Y, Kawamoto K, Nakai Y. A multicentre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica. 1984;3:526-530.
  19. Moriya N, Nakata M, Nakamura M, et al. Intestinal absorption of serrapeptase (TSP) in rats. Biotechnol Appl Biochem. 1994;20(Pt 1):101-108.
  20. Conticello S, Malannino H, Serra A. La serratiopeptidasi in ORL. Nuova Clin ORL. 1979;31:15-20.
  21. Kakinuma A, Moriya N, Kawahar K, et al., Regression of fibrinolysis in scalded rats by administration of Serratia protease. Biochem Pharmacol. 1982;31:2861-2866.
  22. Marty M. Enzymotherapie anti-inflammatoire a l’ aide de la serrapeptase: resultas cliniques en traumatology et en ORL. CR Therapeut. 1985;3:9-19.
  23. Elies W, Mevissen M, Rucker HJ, et al., Akute und subakute Entzundungen der Nasennenbenholen. Z Allmeinmed. 1987;4:92-95.
  24. Harada Y. Clinical efficacy of Danzen on buccal swelling after radical operation for chronic sinusitis. Igaku Ayumi. 1982;123:768-778.
  25. Matsudo A, Taniguchi T, Hiratsuta M, et al., Effect of serratiiopeptidase (Danzen) on inflammation edema following operation for thyroid disease. Med Consult New Remedy. 1981;18:171-175.
  26. Maheshwari M, Miglani G, Mali A, Paradkar A, Yamamura S, Kadam S. Development of tetracycline-serratiopeptidase-containing periodontal gel: formulation and preliminary clinical study. AAPS PharmSciTech. 2006;15:76 e1-e10.
  27. Yamazaki H, Tsuji H: Anti-inflammatory activity of TSP, a protease produced by a strain of Serratia. Folia Pharmacol Japan 1967, 63, 302-314.
  28. Sobel RA, Mitchell ME. Fibronectin in multiple sclerosis lesions. Am J Pathol. 1989;135:161-168.
  29. Gveric D, Hanemaaijer R, Newcombe J, van Lent NA, Sier CF, Cuzner ML. Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain. 2001;124(Pt 10):1978-1988.
  30. Pretorius E, Oberholzer HM. Ultrastructural changes of platelets and fibrin networks in human asthma: a qualitative case study. Blood Coagul Fibrinolysis. 2009;20(2):146-149.
  31. Cowburn, A. S., Condliffe, A. M., Farahi, N., Summers, C., Chilvers, E. R. (2008). Advances in neutrophil biology: clinical implications. Chest. 2008 Sep;134(3):606-12.
  32. Hallow KM, Taylor WR, Rachev A, Vito RP. Markers of inflammation collocate with increased wall stress in humans coronary arterial plaque. Biomech Model Mechanobiol. 2009;8(6):473-86.
  33. Arthritis/Rheumatoid Arthritis’. Serrapeptase Info. n.p. n.d. Web. 3 May, 2011.
  34. The History of Serrapeptase’. N.A. n.p. n.d. Web. 4th May, 2011
  35. Harada Y: Clinical efficacy of Danzen on buccal swelling after radical operation for chronic sinusitis. Igaku Ayumi 1982, 123:768-778.
  36. Protect Your Heart and Reduce Inflammation with Serrapeptase’. Wellness Watchers MD. n.p. n.d. Web. 2nd May, 2011.
  37. Chopra D, Rehan HS, Mehra P, Kakkar AK. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. Int J Oral Maxillofac Surg. 2009;38(4):350-355.
  38. Merten HA, Müller K, Drubel F, Halling F. Volumetric verification of edema protection with Serrapeptase after third molar osteotomy. Dtsch Z Mund Kiefer Gesichtschir.1991;15(4):302-305.
  39. Pant KK, Das V, Grawal SP, et al. PARFLEX – a very useful drug for management of surgical pain. J Indian Med Assoc. 2008;106(6):409-411.
  40. Longhi C, Scoarughi GL, Poggiali F, Cellini A, Carpentieri A, Seganit L, Pucci P, Amoresano A, Cocconcelli PS, Artini M, Costerton JW, SelanL. Protease treatment affects both invasion ability and biofilm formation in Listeria monocytogenes. Microb Pathog. 2008;45(1):45-52.
  41. Koyama A, Mori J, Tokuda H, et al. Augmentation by serrapeptase of tissue permeation by cefotiam. Jpn J Antibiot. 1986;39(3):761-771.
  42. Okumura H, Watanabe R, Kotoura Y, Nakane Y, Tangiku O. Effects of a proteolytic-enzyme preparation used concomitantly with an antibiotic in osteoarticular infections. Jpn J Antibiot. 1977;30(3):223-227.
  43. Aratani H, Tateishi H, Negita S. Studies on the distributions of antibiotics in the oral tissues: Experimental staphylococcal infection in rats, and      effect of serratiopeptidase on the distributions of antibiotics. Jpn J Antibiot. 1980;33(5):623-635.
  44. Majima Y, Hirata K, Takeuchi K, Hattori M, Sakakura Y. Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. An Rev Respir Dis 1990;141(1):79-83
  45. Majima Y, Inagaki M, Hirata K, Takeuchi K, Morishita A, Sakakura Y. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. Arch Otorhinolaryngol. 1988;244(6):355-359.
  46. Bracale G, Selvetella L. Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase. Minerva Cardioangiol. 1996;44(10):515-524.
  47. Kasé Y, Seo H, Oyama Y, et al. A new method for evaluating mucolytic expectorant activity and its application. II. Application to two proteolytic enzymes, serratiopeptidase and seaprose. Arzneimittelforschung. 1982;32(4):374-378.
  48. Shimura S, Okubo T, Maeda S, Aoki T, Tomioka M, Shindo Y, Takishima T, Umeya K. Effect of expectorants on relaxation behavior of sputum viscoelasticity in vivo. Biorheology 1983;20(5):677-83.
  49. KV S, Devi GS, Mathew ST. Liposomal formulations of serratiopeptidase: in vitro studies using PAMPA and Caco-2 models. Mol Pharm. 2008;5(1):92-97.
  50. Sandhya KV, Devi SG, Mathew ST. Quantitation of serrapeptase in formulations by UV method in the microplate format. Curr Drug Deliv. 2008;5(4):303-305.
  51. Meletis CD, Barker JE. Therapeutic enzymes: using the body's helpers as healers. Alt Comp Ther. 2005;74-77.
  52. ‘The Use of Serrapeptase.’ Live Strong. n.p. 29July, 2010. Web. 1 May, 2011.
  53. Sumi H, Hamada H, Tsushima H, Mihara H, Muraki H. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia. 1987;43:1110-1111.
  54. Pais E, Alexy T, Holsworth RE Jr, Meise HJ. Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc. 2006;35:139-142.
  55. Milner M, Makise K. Natto and its active ingredient nattokinase: a potent and safe thrombolytic agent. Alt Comp Therap. 2002;8(3):157-164.
  56. Fujita M, Hong K, Ito Y, et al. Thrombolytic effect of nattokinase on a chemically-induced thrombosis model in rat. Biol Pharm Bull. 1995;18:1387-1391.
  1. The Miracle Enzyme is Serrapeptase.’ Quality Enzymes. n.p. n.d. Web. 30 April, 2011.
  2. Al-Khateeb TH, Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. Int J Oral Maxillofac Surg. 2008;37(3): 264-268
  3. What is Serrapeptase?’ Live Strong. n.p. 06th July, 2010. Web. 30 April, 2011.
  4. Silk Worm Enzymes for Carotid Artery Blockage. Naturally Healthy Publications. n.d. Web. 2 March, 2013.
  5. Mico´-Llorens JM, Satorres-Nieto M, Gargallo-Albiol J, Arnabat- Domı´nguez J, Berini-Ayte´s L, Gay- Escoda C. Efficacy of methylprednisolone in controlling complications after impacted lower third molar surgical extraction. Eur J Clin Pharmacol. 2006;62(9):693-698.
  6. Ustun Y, Erdogan O, Esen E, Karsli ED. Comparison of the effects of 2 doses of methylprednisolone on pain, swelling, and trismus after third molar surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003: 96: 535-539.
  7. Graziani F, D’Aiuto F, Arduino PG, Tonelli M, Gabriele M. Perioperative dexamethasone reduces post-surgical sequelae of wisdom tooth removal. A split mouth randomized double-masked clinical trial. Int J Oral Maxillofac Surg. 2006: 35: 241-246.
  8. Al-Khateeb TH, Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. Int J Oral Maxillofac Surg. 2008;37(3):264-268.
  9. Esch PM, Gerngross H, Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase- a prospective study. Fortschr Med. 1989;107:67-68.
  10. Kee WH, Tan SL, Lee V, Salmon YM. The treatment of breast engorgement with Serrapeptase (Danzen): a randomized double-blind controlled trial. Singapore Med J 1989: 30: 48-54.
  11. Klein G, Kullich W. Short-term treatment of painful osteoarthritis of the knee with oral enzymes: randomised, doubleblind study versus Diclofenac. Clin Drug Invest 2000;19:15-23.
  12. Lee HS, Majima Y, Sakakura Y, Kim BW. A technique for quantitative cytology of nasal secretions. Eur Arch Otorhinolaryngol. 1991;248:406-408.
  13. Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A, Russo S, Guarini E, Vesperini G. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind randomized trial versus placebo. J Int Med Res. 1990;18:379-388.
  14. Mecikoglu M, Saygi B, Yildirim Y, Karadag-Saygi E, Ramadan SS, Esemenli T. The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infection. J Bone Joint Surg Am. 2006;88:1208-1214.
  15. Nakamura S, Hashimoto Y, Mikami M, Yamanaka E, Soma T, Hino M, Azuma A, Kudoh S. Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Respirology. 2003;8:316-320.
  16. Panagariya A, Sharma AK. A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome. J Assoc Physicians India 1999;47:1170-1172.
  17. Selan L, Berlutti F, Passariello C, Comodi-Ballanti MR, Thaller MC. Proteolytic enzymes: a new treatment strategy for prosthetic infections. Antimicrob Agents Chemother. 1993;37:2618-2621.
  18. Tachibana M, Mizukoshi O, Harada Y, Kawamoto K, Nakai Y. A multicentre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica. 1984;3:526-530.
  19. Moriya N, Nakata M, Nakamura M, et al. Intestinal absorption of serrapeptase (TSP) in rats. Biotechnol Appl Biochem. 1994;20(Pt 1):101-108.
  20. Conticello S, Malannino H, Serra A. La serratiopeptidasi in ORL. Nuova Clin ORL. 1979;31:15-20.
  21. Kakinuma A, Moriya N, Kawahar K, et al., Regression of fibrinolysis in scalded rats by administration of Serratia protease. Biochem Pharmacol. 1982;31:2861-2866.
  22. Marty M. Enzymotherapie anti-inflammatoire a l’ aide de la serrapeptase: resultas cliniques en traumatology et en ORL. CR Therapeut. 1985;3:9-19.
  23. Elies W, Mevissen M, Rucker HJ, et al., Akute und subakute Entzundungen der Nasennenbenholen. Z Allmeinmed. 1987;4:92-95.
  24. Harada Y. Clinical efficacy of Danzen on buccal swelling after radical operation for chronic sinusitis. Igaku Ayumi. 1982;123:768-778.
  25. Matsudo A, Taniguchi T, Hiratsuta M, et al., Effect of serratiiopeptidase (Danzen) on inflammation edema following operation for thyroid disease. Med Consult New Remedy. 1981;18:171-175.
  26. Maheshwari M, Miglani G, Mali A, Paradkar A, Yamamura S, Kadam S. Development of tetracycline-serratiopeptidase-containing periodontal gel: formulation and preliminary clinical study. AAPS PharmSciTech. 2006;15:76 e1-e10.
  27. Yamazaki H, Tsuji H: Anti-inflammatory activity of TSP, a protease produced by a strain of Serratia. Folia Pharmacol Japan 1967, 63, 302-314.
  28. Sobel RA, Mitchell ME. Fibronectin in multiple sclerosis lesions. Am J Pathol. 1989;135:161-168.
  29. Gveric D, Hanemaaijer R, Newcombe J, van Lent NA, Sier CF, Cuzner ML. Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain. 2001;124(Pt 10):1978-1988.
  30. Pretorius E, Oberholzer HM. Ultrastructural changes of platelets and fibrin networks in human asthma: a qualitative case study. Blood Coagul Fibrinolysis. 2009;20(2):146-149.
  31. Cowburn, A. S., Condliffe, A. M., Farahi, N., Summers, C., Chilvers, E. R. (2008). Advances in neutrophil biology: clinical implications. Chest. 2008 Sep;134(3):606-12.
  32. Hallow KM, Taylor WR, Rachev A, Vito RP. Markers of inflammation collocate with increased wall stress in humans coronary arterial plaque. Biomech Model Mechanobiol. 2009;8(6):473-86.
  33. Arthritis/Rheumatoid Arthritis’. Serrapeptase Info. n.p. n.d. Web. 3 May, 2011.
  34. The History of Serrapeptase’. N.A. n.p. n.d. Web. 4th May, 2011
  35. Harada Y: Clinical efficacy of Danzen on buccal swelling after radical operation for chronic sinusitis. Igaku Ayumi 1982, 123:768-778.
  36. Protect Your Heart and Reduce Inflammation with Serrapeptase’. Wellness Watchers MD. n.p. n.d. Web. 2nd May, 2011.
  37. Chopra D, Rehan HS, Mehra P, Kakkar AK. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. Int J Oral Maxillofac Surg. 2009;38(4):350-355.
  38. Merten HA, Müller K, Drubel F, Halling F. Volumetric verification of edema protection with Serrapeptase after third molar osteotomy. Dtsch Z Mund Kiefer Gesichtschir.1991;15(4):302-305.
  39. Pant KK, Das V, Grawal SP, et al. PARFLEX – a very useful drug for management of surgical pain. J Indian Med Assoc. 2008;106(6):409-411.
  40. Longhi C, Scoarughi GL, Poggiali F, Cellini A, Carpentieri A, Seganit L, Pucci P, Amoresano A, Cocconcelli PS, Artini M, Costerton JW, SelanL. Protease treatment affects both invasion ability and biofilm formation in Listeria monocytogenes. Microb Pathog. 2008;45(1):45-52.
  41. Koyama A, Mori J, Tokuda H, et al. Augmentation by serrapeptase of tissue permeation by cefotiam. Jpn J Antibiot. 1986;39(3):761-771.
  42. Okumura H, Watanabe R, Kotoura Y, Nakane Y, Tangiku O. Effects of a proteolytic-enzyme preparation used concomitantly with an antibiotic in osteoarticular infections. Jpn J Antibiot. 1977;30(3):223-227.
  43. Aratani H, Tateishi H, Negita S. Studies on the distributions of antibiotics in the oral tissues: Experimental staphylococcal infection in rats, and      effect of serratiopeptidase on the distributions of antibiotics. Jpn J Antibiot. 1980;33(5):623-635.
  44. Majima Y, Hirata K, Takeuchi K, Hattori M, Sakakura Y. Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. An Rev Respir Dis 1990;141(1):79-83
  45. Majima Y, Inagaki M, Hirata K, Takeuchi K, Morishita A, Sakakura Y. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. Arch Otorhinolaryngol. 1988;244(6):355-359.
  46. Bracale G, Selvetella L. Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase. Minerva Cardioangiol. 1996;44(10):515-524.
  47. Kasé Y, Seo H, Oyama Y, et al. A new method for evaluating mucolytic expectorant activity and its application. II. Application to two proteolytic enzymes, serratiopeptidase and seaprose. Arzneimittelforschung. 1982;32(4):374-378.
  48. Shimura S, Okubo T, Maeda S, Aoki T, Tomioka M, Shindo Y, Takishima T, Umeya K. Effect of expectorants on relaxation behavior of sputum viscoelasticity in vivo. Biorheology 1983;20(5):677-83.
  49. KV S, Devi GS, Mathew ST. Liposomal formulations of serratiopeptidase: in vitro studies using PAMPA and Caco-2 models. Mol Pharm. 2008;5(1):92-97.
  50. Sandhya KV, Devi SG, Mathew ST. Quantitation of serrapeptase in formulations by UV method in the microplate format. Curr Drug Deliv. 2008;5(4):303-305.
  51. Meletis CD, Barker JE. Therapeutic enzymes: using the body's helpers as healers. Alt Comp Ther. 2005;74-77.
  52. ‘The Use of Serrapeptase.’ Live Strong. n.p. 29July, 2010. Web. 1 May, 2011.
  53. Sumi H, Hamada H, Tsushima H, Mihara H, Muraki H. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia. 1987;43:1110-1111.
  54. Pais E, Alexy T, Holsworth RE Jr, Meise HJ. Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc. 2006;35:139-142.
  55. Milner M, Makise K. Natto and its active ingredient nattokinase: a potent and safe thrombolytic agent. Alt Comp Therap. 2002;8(3):157-164.
  56. Fujita M, Hong K, Ito Y, et al. Thrombolytic effect of nattokinase on a chemically-induced thrombosis model in rat. Biol Pharm Bull. 1995;18:1387-1391.